BioNexus Gene Lab Stock Edges Up While Nasdaq Microcap Faces Chemrex Cash Battle
BioNexus Gene Lab Corp. rose 1.45% to $2.10 in light Nasdaq trading Wednesday, with under 3,000 shares changing hands. First-quarter revenue dropped to $22,842 from $2.14 million a year ago, mainly due to weaker Chemrex results. The company is seeking to recover $2.94 million from former Chemrex officers over disputed payments. BioNexus warned of “substantial doubt” about its ability to continue as a going concern.